Ceribell Publishes Multi-Center Retrospective Study Results

Ceribell, a commercial-stage medical technology company focused on transforming the detection and management of patients with serious neurological conditions, has announced the publication of results from a new multi-center retrospective study of patient outcomes following use of the Ceribell system compared to conventional electroencephalography (EEG). 

 

The study was published in Neurocritical Care, the journal of the Neurocritical Care Society.

 

Study findings associated the use of Ceribell with a significant reduction in length of stay in the ICU, fewer patients discharged with poor functional disability scores, and faster door-to-EEG time compared to conventional EEG.

 

Other key findings included 4.1 days shorter median ICU length of stay with Ceribell vs. conventional EEG; 18% point decrease in the rate of patients discharged with poor modified Rankin Scale scores (an indicator of functional disability) when patients were assessed with Ceribell vs. conventional EEG; and 19 hours faster median time to EEG acquisition with the Ceribell System, 5.9 hours with Ceribell vs. 25.3 hours with conventional EEG.

 

“These study results underscore the critical need for early assessment with point-of-care EEG, and the ability for providers to improve patient care while reducing length of stay and strain on hospital personnel through use of the Ceribell system,” said Jane Chao, Ph.D., Ceribell Co-founder and CEO. “The meaningful association between frontline access to Ceribell’s point-of-care EEG and improved patient outcomes will continue to drive our commitment to revolutionizing neurodiagnostics.”

 

The primary SAFER-EEG study was conducted at four academic hospitals in the United States. Results were recently published in Neurology and demonstrate that Ceribell point-of-care EEG performs comparably to conventional EEG in forecasting seizure risk for acutely ill patients using the 2HELPS2B score.